Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

Approval: Royal Flying Doctor Service - Western Operations - Eaton

I, Christine Maree Connors, Chief Health Officer:

(a) under section 254(1) of the Act, approve each Scheduled substance treatment protocol

specified in Schedule A, and

(b) under section 254(3) of the Act, state that each Schedule Substance Treatment

Protocol specified in Schedule A remains in effect for a period of 2 years on and from

the date of this Notice.

Dated 13/06/2024

Chief Health Officer

## Schedule A

Title	Publication Date	Author
Royal Flying Doctor Service –	5 June 2024	Royal Flying Doctor Service –
Western Operations – Eaton		Western Operations
administration protocol		

## Royal Flying Doctor Service - Western Operations-Eaton administration protocol

Area Applicable	Services delivered at or through RFDS Western Operations based at 15B Lancaster Road, Eaton			
Health Professionals authorised by this SSTP	Paramedics and Nurses employed by or contracted to Royal Flying Doctor Service-Western Operations (ABN 29 067 077 696)			
Scheduled Substance	Adenosine	Metaraminol		
	Amiodarone	Methoxyflurane		
	Aspirin	Metoclopramide		
	Atropine	Midazolam		
	Benztropine	Naloxone		
	Benzylpenicillin	Ondansetron		
	Ceftriaxone	Oxytocin		
	Clopidogrel	Pantoprazole		
	Dexamethasone	Potassium chloride		
	Diazepam	Prochlorperazine		
	Droperidol	Promethazine		
	Enoxaparin	Propofol		
	Epinephrine (Adrenaline)	Rocuronium		
	Ergometrine	Ropivacaine		
	Flucloxacillin	Salbutamol		
	Furosemide	Suxamethonium		
	Gentamicin	Tenecteplase		
	Glucagon	Tranexamic Acid		
	Glyceryl Trinitrate	Vecuronium		
	Heparin			
	Hydralazine	Schedule 8 substances		
	Hydrocortisone	Fentanyl		
	Ibuprofen	Ketamine		
	Insulin Morphine			
	Ipratropium bromide	Oxycodone		
Indication	As per RFDS Queensland – Primary Clinical Care Manual – 11 <sup>th</sup> Edition 2022			
Contraindicatio ns and/or Exclusions*	As per RFDS Queensland – Primary Clinical Care Manual – 11 <sup>th</sup> Edition 2022			
Dose and Route	As per RFDS Queensland – Primary Clinical Care Manual – 11 <sup>th</sup> Edition 2022			
Administration	As per RFDS Queensland – Primary Clinical Care Manual – 11 <sup>th</sup> Edition 2022			



Dose Frequency	As per RFDS Queensland – Primary Clinical Care Manual – 11 <sup>th</sup> Edition 2022			
Drug Interactions	As per RFDS Queensland – Primary Clinical Care Manual – 11 <sup>th</sup> Edition 2022			
Monitoring requirements	As per RFDS Queensland – Primary Clinical Care Manual – 11 <sup>th</sup> Edition 2022			
Health Professional Accreditation Requirements	<ul> <li>Paramedics:         <ul> <li>Be registered with the Paramedicine Board of Australia with no conditions, undertakings or notations which may limit delivery of clinical services directly to patients.</li> </ul> </li> <li>Maintain continuing professional development related to skills and competencies required for the delivery of medicines.</li> <li>Nurses:         <ul> <li>Be registered with the Nursing and Midwifery Board of Australia with no conditions, undertakings or notations which may limit delivery of clinical services directly to patients</li> <li>Maintain continuing professional development related to skills and competencies required for the delivery of medicines</li> </ul> </li> </ul>			
Documentation (including necessary	As per RFDS Queensland – Primary Clinical Care Manual – 11 <sup>th</sup> Edition 2022			
information to the patient)				
Chief Health Officer	Signature	Name	Date	
	EDOC2024/160104	Christine Connors	13/06/2024	
Period of effect	This SSTP remains in force until 13/02/2026 unless revoked earlier			

## References:

<sup>\*</sup> The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration